This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
RedHill Biopharma Ltd., a biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel.View RDHL key stats
Redhill Biopharma Ltd - RDHL - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Redhill Biopharma Ltd as a
Sell with a ratings score of D.
Report Snippet: We rate REDHILL BIOPHARMA LTD (RDHL) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.